Supply Chain | May 14, 2024
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA before special items falls 1.3 percent to € 4.41 billion
Lupin updates on shipment of Mirabegron ER Tablets
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
The company is committed to address this observation comprehensively within stipulated time
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subscribe To Our Newsletter & Stay Updated
